Both of these points are likely to be of relevance to the management of patients with AF. Patients with heart failure, irrespective of ejection fraction, frequently have AF. Disentangling whether a ...

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in ...

All Exo AI runs directly on Exo Iris®, eliminating lag, reducing costs, and enabling expert-level diagnostics in any setting. With ten FDA-cleared AI indications, Exo is setting a new standard in fast ...

Severity of cardiometabolic comorbidity burden affects risk for all-cause hospitalization in patients with heart failure.

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

A gene therapy for heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, has shown ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...